Franklin Resources Inc. Increases Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Franklin Resources Inc. lifted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 5.8% in the third quarter, HoldingsChannel.com reports. The firm owned 104,141 shares of the company’s stock after purchasing an additional 5,687 shares during the period. Franklin Resources Inc.’s holdings in Health Catalyst were worth $857,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of HCAT. First Light Asset Management LLC lifted its holdings in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after buying an additional 3,221,408 shares during the period. Impax Asset Management Group plc grew its position in shares of Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares during the period. Millennium Management LLC boosted its position in shares of Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after purchasing an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA grew its stake in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Daventry Group LP increased its stake in Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after purchasing an additional 84,178 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the transaction, the insider now directly owns 98,702 shares in the company, valued at $777,771.76. This trade represents a 6.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the sale, the insider now owns 236,950 shares of the company’s stock, valued at $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,051 shares of company stock worth $563,515 over the last quarter. Insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

HCAT has been the topic of several recent analyst reports. Citigroup lifted their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Stephens increased their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Royal Bank of Canada raised their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.79.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $7.08 on Monday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $430.80 million, a P/E ratio of -5.24 and a beta of 1.31. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The business’s 50-day moving average is $7.96 and its 200 day moving average is $7.48.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.22) earnings per share. On average, equities research analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.